The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Abstract
OBJECTIVE: Few long-term studies have compared the efficacy and safety of typical and atypical antipsychotic medications directly in patients with a first episode of psychosis who met the criteria for schizophrenia or a related psychotic disorder. This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial. METHOD: Patients with first-episode psychosis (N=263) were randomly assigned under double-blind conditions to receive haloperidol or olanzapine and were followed for up to 104 weeks. Domains measured included psychopathology, psychosocial variables, neurocognitive functioning, and brain morphology and metabolism. This report presents data from clinical measures of treatment response and safety data from the 12-week acute treatment phase. RESULTS: Haloperidol and olanzapine were associated with substantial and comparable baseline-to-endpoint reductions in symptom severity, which did not differ significantly in last-observation-carried-forward analyses. However, in a mixed-model analysis, olanzapine-treated subjects had significantly greater decreases in symptom severity as measured by the Positive and Negative Syndrome Scale total score and negative and general scales and by the Montgomery-Asberg Depression Rating Scale but not as measured by the Positive and Negative Syndrome Scale positive scale and by the Clinical Global Impression severity rating. Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients. Overall, significantly more olanzapine-treated subjects than haloperidol-treated subjects completed the 12-week acute phase of the study (67% versus 54%). CONCLUSIONS: As expected on the basis of previous studies, both olanzapine and haloperidol were effective in the acute reduction of psychopathological symptoms in this group of patients with first-episode psychosis. However, olanzapine had several relative advantages in therapeutic response. Although the nature of adverse events differed between the two agents, retention in the study was greater with olanzapine. Retention in treatment is important in this patient population, given their risk of relapse. Longer-term results are needed to determine whether treatment with atypical antipsychotics results in superior outcomes for a first episode of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 1×
“cognitive function, greater relapse prevention, and reduced loss of gray matter volume, have been reported separately (32, 33), as well as with other drugs in different patient populations (34, 35), suggesting potentially superior therapeutic actions of atypical antipsychotic drug treatment.”
ResultRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Self-citationGeddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
One hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Self-citationCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466
Self-citationMcEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 381
Self-citationLieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Self-citationPhenothiazine Treatment in Acute Schizophrenia: Effectiveness
(1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210028005 · Cited by 334
Mechanisms of action of atypical antipsychotic drugs: a critical analysis
Kinon, B. J., & Lieberman, J. A. (1996) · Psychopharmacology · doi:10.1007/bf02245602 · Cited by 317
Self-citationGuttmacher, M. S. (1964) · PubMed · Cited by 310
Kane, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070083010 · Cited by 273
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 217
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, Jr., & Tollefson, G. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.79 · Cited by 215
Self-citation(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1724 · Cited by 194
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
Lieberman, J. A. (1996) · PubMed · Cited by 167
Self-citationSchizophrenia: A Follow-up Study of the Results of Five Forms of Treatment
May, P. R. A. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780320056006 · Cited by 166
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos, M., Alvir, J. M., Woerner, M. G., Koreen, A., Geisler, S., Mayerhoff, D., Sobel, S., Kane, J. M., Borenstein, M., & Lieberman, J. A. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830040049009 · Cited by 140
Self-citationThe McLean First-episode Psychosis Project: Six-month Recovery and Recurrence Outcome
Tohen, M. F., Stoll, A. L., Strakowski, S. M., Faedda, G. L., Mayer, P., Goodwin, D. C., Kolbrener, M., & Madigan, A. M. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.2.273 · Cited by 135
Self-citationThe Evaluation and Treatment of First-episode Psychosis
Sheitman, B., Lieberman, P., Lee, H., & Strauss, R. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.653 · Cited by 120
Lieberman, J. A., Sheitman, B., Chakos, M., et al. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804001-00005 · Cited by 72
Self-citationGreen, A. I., & Schildkraut, J. J. (1995) · Harvard Review of Psychiatry · doi:10.3109/10673229509017159 · Cited by 40
Self-citation
Cited by
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Self-citationMitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Metadata
- Authors
- Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., Wei, H., Hamer, R. M., & the HGDH Study Group
- Venue
- American Journal of Psychiatry
- Published
- 2003-08-01
- Volume
- 160
- Issue
- 8
- Pages
- 1396-1404
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2137984107
- Cited by
- 404
- References
- 31
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.